Every year, tens of thousands of lives are silently stolen by a hidden crisis in India—snakebites. But here's where it gets controversial: while many see this as a tragic yet unavoidable part of rural life, others argue that these deaths are a stark reminder of systemic failures in healthcare and infrastructure. Let’s dive into this alarming issue and uncover why it’s far more complex—and solvable—than most realize.
Imagine being a farmer in India, like Devendra, who vividly recalls the moment a snake struck his leg while he was picking mulberry leaves. 'I waited four days before the pain became unbearable and I finally went to the hospital,' he shares in a film by the Global Snakebite Taskforce (GST). 'That delay cost me my leg.' Devendra is one of the fortunate few who survived. According to India’s federal government, approximately 50,000 people die from snakebites annually—nearly half of all such deaths worldwide. Shockingly, some estimates suggest the toll could be even higher, with up to 1.2 million deaths between 2000 and 2019, averaging 58,000 per year.
And this is the part most people miss: a new GST report reveals that 99% of healthcare workers in India struggle to administer antivenom, the life-saving treatment that neutralizes snake venom. Researchers surveyed 904 medical professionals across India, Brazil, Indonesia, and Nigeria—countries hardest hit by snakebites—and found common barriers: poor infrastructure, limited access to antivenom, and inadequate training. Nearly half reported that treatment delays led to severe complications, including amputations, surgeries, or lifelong mobility issues.
Snakebites disproportionately affect impoverished rural communities in low- and middle-income countries. In India, the central and eastern regions bear the brunt of these tragedies, with farmers and tribal communities at highest risk. Dr. Yogesh Jain, a GST member and practitioner in Chhattisgarh, explains, 'Snakebites are seen as a poor person’s problem, which is why there isn’t enough outrage or action over these entirely preventable deaths. Every second counts when treating a snakebite.'
In 2024, India launched the National Action Plan for Prevention and Control of Snakebite Envenoming (NAPSE), aiming to halve snakebite deaths by 2030. The plan focuses on improved surveillance, better antivenom availability, enhanced medical training, and public awareness. While experts applaud this initiative, its implementation remains inconsistent.
Here’s where it gets even more complicated: snake venom acts fast, entering the bloodstream within minutes and attacking nerves, cells, or the circulatory system. Delays in treatment can lead to respiratory failure, paralysis, or organ failure. Yet, in rural India, bad roads, distant hospitals, and a lack of ambulances often prevent timely care. Last September, a pregnant woman in Gujarat reportedly died after her family had to carry her 5 kilometers in a cloth sling because no vehicle could reach their village.
Some states are trying to improve access by stocking antivenom in local health centers, but administering it correctly remains a challenge. Many health workers lack proper training and fear giving antivenom due to potential adverse reactions. 'The antivenom is mixed with saline and injected intravenously over an hour, but many centers aren’t equipped to handle side effects,' Dr. Jain notes.
Another issue? Many rural Indians still rely on faith healers or traditional remedies, seeking hospital care only when symptoms worsen—often too late. Gerry Martin, co-founder of The Liana Trust, highlights another hurdle: the lack of high-quality antivenom. India’s current antivenom only protects against the 'big four' snakes—spectacled cobra, common krait, Russell’s viper, and saw-scaled viper—responsible for most bites. But dozens of other venomous species, like the green pit viper in Himachal Pradesh or the Malabar pit viper in southern states, lack targeted treatments.
A 2023 study by AIIMS Jodhpur found that when antivenom for saw-scaled vipers was given to 105 patients with unknown snake species, two-thirds didn’t respond well. The study concluded that 'region-specific antivenom is urgently needed.' The Liana Trust has been researching venoms beyond the big four for five years, but progress is slow due to the labor-intensive process.
Martin urges states to follow Karnataka’s lead, which declared snakebites a 'notifiable disease,' requiring health professionals to report cases to combat under-reporting. Dr. Jain sums it up bluntly: 'Snakebite deaths start where political will ends. Governments must ensure poor people don’t get poor health systems. They deserve better.'
Now, here’s a thought-provoking question for you: Is the snakebite crisis in India a failure of healthcare, infrastructure, or societal priorities? Or is it a combination of all three? Share your thoughts in the comments—let’s spark a conversation that could save lives.
